



(12) Translation of
European patent specification

(11) NO/EP 2477648 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 39/00 (2006.01)

C07K 16/28 (2006.01)

C12P 21/08 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.11.07
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.07.20
(86)	European Application Nr.	10817793.2
(86)	European Filing Date	2010.09.15
(87)	The European Application's Publication Date	2012.07.25
(30)	Priority	2009.09.15, US, 276726 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; SE; SI; SK; SM; TR
(73)	Proprietor	The Board of Trustees of the Leland Stanford Junior University, Office of the General Counsel Building 170, Third Floor, Main Quad P.O. Box 20386, Stanford, CA 94305-2038, USA
(72)	Inventor	WEISSMAN, Irving L., 747 Santa Ynez Street, Stanford, CA 94305, USA MAJETI, Ravindra, Stanford Institute for Stem Cell Bio and Regenerative Medicine 1050 Arastradero Road Building A, Stanford, CA 94304, USA ALIZADEH, Arash Ash, 328 Greenfield Avenue, San Mateo, CA 94403, USA CHAO, Mark P., 2001 Showers Drive, Mountain View, CA 94040, USA
(74)	Agent or Attorney	AWA NORWAY AS, Hoffsvæien 1A, 0275 OSLO, Norge
(54)	Title	SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS
(56)	References Cited:	WO-A1-2008/121821, WO-A1-2009/091547, US-A1- 2008 107 654, WO-A1-2009/091601, US-A1- 2007 041 981, US-A1- 2009 191 202, CHAMES PATRICK ET AL: "Bispecific antibodies for cancer therapy. The light at the end of the tunnel?", MABS, LANDES BIOSCIENCE, US, vol. 1, no. 6, 1 November 2009 (2009-11-01), pages 539-547, XP002688758, ISSN: 1942-0862, DOI: 10.4161/MABS.1.6.10015 DAFNE MÜLLER AND ROLAND KONTERMANN ED - STEFAN DÜBEL: "Handbook of Therapeutic antibodies; Part III, Chapter 2 :Bispecific Antibodies", 1 February 2008 (2008-02-01), HANDBOOK OF THERAPEUTIC ANTIBODIES, WILEY-VCH, WEINHEIM, PAGE(S) 352 - 378, XP002541368, ISBN: 978-3-527-31453-9 CHAO MARK P ET AL: "Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts", BLOOD, vol. 114, no. 22, November 2009 (2009-11), pages 1063-1064, XP009168477, & 51ST ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 05 - 08, 2009 ELIE DHEILLY ET AL: "Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies", MOLECULAR THERAPY, vol. 25, no. 2, 1 February 2017 (2017-02-01), pages 523-533, XP055407335, US ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2016.11.006

BAEUEERLE PATRICK A ET AL: "Bispecific T-cell engaging antibodies for cancer therapy", CANCER RESEARCH, AACR, US PHILADELPHIA, PA, vol. 69, no. 12, 15 June 2009 (2009-06-15) , pages 4941-4944, XP002665118, ISSN: 1538-7445, DOI: 10.1158/0008-5472.CAN-09-0547 [retrieved on 2009-06-09]

CHAO M P ET AL: "CD47 IS AN ADVERSE PROGNOSTIC FACTOR IN NON-HODGKIN LYMPHOMA AND A THERAPEUTIC ANTIBODY TARGET THAT SYNERGIZES WITH RITUXIMAB", EXPERIMENTAL HEMATOLOGY (NEW YORK), vol. 37, no. 9, Suppl. 1, 9 September 2009 (2009-09-09), - 12 September 2009 (2009-09-12), pages S8-S9, XP009168476, & 38TH ANNUAL SCIENTIFIC MEETING OF THE ISEH-SOCIETY-FOR-HEMATOLOGY-AND-STEM-CELLS ; ATHENS, GREECE; SEPTEMBER 09 -12, 2009 ISSN: 0301-472X

EMILY C PICCIONE ET AL: "A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells", MABS, vol. 7, no. 5, 17 June 2015 (2015-06-17), pages 946-956, XP055314609, US ISSN: 1942-0862, DOI: 10.1080/19420862.2015.1062192

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Synergistisk kombinasjon av midler for anvendelse ved behandling av hematologisk kreft i en pasient, hvor den hematologiske kreft er ikke-Hodgkins lymfom (NHL) og hvor NHL'et er et diffust bredt B-cellelymfom, hvor
- 5 kombinasjonen av midler omfatter et første middel som selektivt blokkerer CD47 og et andre middel som bindes til CD20, hvor det første og andre middel er omfattet i et bispesifikt FcR-engasjerende antistoff som er selektivt for CD47 og CD20.